Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | SLC5A7 | Q9GZV3 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | WNT1 | P04628 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18871751 | 0.87 | OPRK1 (0.69) | OPRK1 | |
| SCHEMBL29505911 | 0.86 | EPHX2 (0.65) | OPRK1KMT2AMEN1EPHX2HRH1 | |
| Hydrochloric Acid SCHEMBL4492052 | 0.86 | OPRK1 (0.67) | OPRK1 | |
| SCHEMBL17339942 | 0.86 | KMT2A (0.54) | OPRK1KMT2AMEN1EPHX2SLC5A7 | |
| SCHEMBL4664688 | 0.85 | SLC5A7 (0.58) | OPRK1KMT2AMEN1SLC5A7CCR3 | |
| SCHEMBL4237314 | 0.85 | HRH3 (0.57) | OPRK1KMT2AMEN1EPHX2SLC5A7 | |
| SCHEMBL17573006 | 0.84 | EPHX2 (0.52) | OPRK1KMT2AMEN1EPHX2SLC5A7 | |
| Hydrochloric Acid SCHEMBL7081383 | 0.84 | HRH3 (0.56) | OPRK1KMT2AMEN1EPHX2SLC5A7 | |
| SCHEMBL930213 | 0.83 | EPHX2 (0.59) | OPRK1KMT2AMEN1EPHX2RAB9A | |
| SCHEMBL931435 | 0.83 | EPHX2 (0.59) | OPRK1KMT2AMEN1EPHX2GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | OPRK1 924/4885KMT2A 2107/4885MEN1 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.